Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | GLA | P06280 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL265454 | 0.90 | GAA (0.57) | USP2GAALMNAKMT2AMEN1 | |
| SCHEMBL265918 | 0.88 | ALDH1A1 (0.60) | USP2GAAKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL263390 | 0.85 | POLB (0.62) | USP2GAAKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL263891 | 0.84 | POLB (0.56) | USP2GAAKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL264309 | 0.83 | CYP3A4 (0.57) | USP2LMNAKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL265104 | 0.82 | POLB (0.57) | USP2GAAKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL265992 | 0.82 | CYP3A4 (0.58) | USP2LMNAKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL265165 | 0.80 | CYP3A4 (0.58) | USP2KMT2AMEN1ALDH1A1MAPT | |
| SCHEMBL264256 | 0.80 | CYP3A4 (0.58) | USP2ALDH1A1MAPTTSHRRXFP1 | |
| SCHEMBL263613 | 0.80 | CYP3A4 (0.71) | LMNAHPGDKMT2AMEN1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8133998-B2 | Bicyclic pyrimidine derivatives as calcium channel blockers | Zalicus Pharmaceuticals, Ltd. (CA) | 2012-03-13 | — | — | US | disclosed |
| US-8133998-B2 | Bicyclic pyrimidine derivatives as calcium channel blockers | Zalicus Pharmaceuticals, Ltd. (CA) | 2012-03-13 | — | — | US | disclosed |
| US-8133998-B2 | Bicyclic pyrimidine derivatives as calcium channel blockers | Zalicus Pharmaceuticals, Ltd. (CA) | 2012-03-13 | — | — | US | disclosed |
| WO-2008138126-A1 | BICYCLIC PYRIMIDINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | NEUROMED PHARMACEUTICALS LTD. (CA) | 2008-11-20 | — | — | WO | disclosed |
| US-20080280900-A1 | BICYCLIC PYRIMIDINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2008-11-13 | — | — | US | disclosed |
| US-20080280900-A1 | BICYCLIC PYRIMIDINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2008-11-13 | — | — | US | disclosed |
| US-20080280900-A1 | BICYCLIC PYRIMIDINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2008-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280900-A1 | BICYCLIC PYRIMIDINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | CACNA1E, CACNA1G, RYR1 | USP2 4768/4885GAA 3277/4885LMNA 2366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.